this paper has some limitations. For one, it only reports on two of the 12 patients who received treatment earliest in the study. It also didn’t show any comparisons to other types of treatments with this type of patient and setting. That said, Kasi said the full results for all twelve patients should be available in the coming months and that his team is also planning future trials with more comprehensive analyses. However, he noted that these results were published because of how effective the drug seemed to be in these preliminary results. “It was not just the kill but how we analyzed the mechanisms of action of the kill,” he said.